Existing differences between available lists of FODMAP-containing foods.

BACKGROUND AND AIM: reduced intake of fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) is useful to treat functional gastrointestinal disorders. However, there is no consensus on which foods should be included in the FODMAP list as FODMAP profile characterization is lacking for many different foods. This study aimed to emphasize the need for a unified FODMAP list to prevent patient confusion. We hypothesized that FODMAP lists do not include all products that may contain high levels of FODMAPs. METHODS: PubMed, ScienceDirect, Scielo, and Cochrane were searched to identify food composition tables, reviews, food analysis publications, laboratory analyses, and clinical trials containing FODMAP lists. RESULTS: of 1,308 articles identified, 10 were selected; 22.6 % of the 204 foods listed were classified differently among studies. This included almonds, avocados, banana, broccoli, soft cheese, eggplant, and walnuts. Nutritional guidance may be taken from existing FODMAP-related literature, but the information given is not always consistent. CONCLUSION: Unvarying lists of low FODMAP foods should be compiled to provide patients with accurate information on FODMAP dieting.

Effects of Gluten on Gut Microbiota in Patients with Gastrointestinal Disorders, Migraine, and Dermatitis.

As gluten may trigger gastrointestinal disorders (GIDs), its presence or absence in the diet can change the diversity and proportion of gut microbiota. The effects of gluten after six weeks of a double-blind, placebo-controlled intervention with a gluten-free diet (GFD) were studied in participants with GIDs suffering from migraines and atopic dermatitis (n = 46). Clinical biomarkers, digestive symptoms, stool, the Migraine Disability Assessment questionnaire, and zonulin levels were analyzed. Next-generation sequencing was used to amplify the 16S rRNA gene of bacteria and the internal transcribed spacer (ITS) regions of fungi. The GFD increased Chao1 fungal diversity after the intervention, while the fungal composition showed no changes. Bacterial diversity and composition remained stable, but a positive association between bacterial and fungal Chao1 diversity and a negative association between Dothideomycetes and Akkermansia were observed. GIDs decreased in both groups and migraines improved in the placebo group. Our findings may aid the development of GID treatment strategies.

Exogenous Supplementation with DAO Enzyme in Women with Fibromyalgia: A Double-Blind Placebo-Controlled Clinical Trial.

Fibromyalgia (FM) is characterized by chronic musculoskeletal pain, muscle tension, joint mobility loss, and several psychological symptoms severely affecting patient well-being. Histamine is naturally degraded in the small intestine by diamine oxidase (DAO). Hereditary or acquired DAO deficiency causes extracellular histamine accumulation, leading to symptoms similar to those of individuals diagnosed with FM. Thus, this study aimed to assess the efficacy of adding DAO supplementation for 8 weeks to their standard therapy. We randomly assigned 100 women with FM (age: 33-61 years) to the supplementation and control groups. The Fibromyalgia Impact Questionnaire (FIQ), the Pain Catastrophizing Scale (PCS), and intensity scales were applied for a series of clinical symptoms together with the Bristol scale to assess the added value of DAO supplementation. Patients in both groups were receiving complete pharmacological support but some differences in the number of subjects receiving analgesics, antidepressants, and anxiolytics was noted. Patients in both study groups experienced favorable changes during the evaluation period as indicated by their final FIQ and PCS scores, particularly in the DAO group in the latter questionnaire. Qualitatively, the patients assigned to the DAO treatment group had lower scores for fatigue, anxiety, depression, burning and for rumination, magnification, and helplessness.

Effect of MetioNac® in patients with metabolic syndrome who are at risk of metabolic dysfunction associated fatty liver disease: a randomized controlled trial.

Introduction: Introduction: metabolic syndrome comprises a combination of diabetes, high blood pressure, and obesity, and metabolic associated fatty liver disease (MAFLD) is associated with it. Objective: to evaluate the effect of supplementation with S-adenosyl-L-methionine + N-acetylcysteine + thioctic acid + vitamin B6 (MetioNac®) for 3 months on lipidic and biochemical parameters in subjects with metabolic syndrome and at risk of MAFLD. The reduction in body weight and the oxidative stress markers malondialdehyde (MDA) and superoxide dismutase (SOD) were also evaluated. Methods: patients with metabolic syndrome, at risk of MAFLD (FIB-4 < 1.30), and with an indication for weight reduction were recruited (n = 15). Control group followed a semipersonalized Mediterranean diet (MD) for weight reduction, according to the recommendations of the Spanish Society for the Study of Obesity (SEEDO). Experimental group, in addition to the MD, took three capsules of MetioNac® supplement per day. Results: compared with the control group, subjects taking MetioNac® showed significant (p < 0.05) reductions in the levels of TG and VLDL-c, as well as in total cholesterol, LDL-c, and glucose levels. They also showed increased levels of HDL-c. Levels of AST and ALT decreased after the intervention with MetioNac®, but this decrease did not reach statistical significance. Weight loss was observed in both groups. Conclusion: supplementation with MetioNac® may be protective against hyperlipidemia, insulin resistance, and overweight among metabolic syndrome patients. Further studies on this issue are needed in a larger population.

Introducción: Introducción: el síndrome metabólico se define como una combinación de diabetes, hipertensión arterial y obesidad, que se asocia con la enfermedad del hígado graso asociada a disfunción metabólica. Objetivo: evaluar el efecto de la suplementación con S-adenosil-L-metionina + N-acetilcisteína + ácido tióctico + vitamina B6 (MetioNac®) durante 3 meses sobre parámetros lipídicos y bioquímicos en sujetos con síndrome metabólico y en riesgo de enfermedad del hígado graso asociada a disfunción metabólica. También se evaluaron la reducción del peso corporal y los marcadores de estrés oxidativo malondialdehído (MDA) y superóxido dismutasa (SOD). Métodos: se reclutaron pacientes con síndrome metabólico, riesgo de enfermedad del hígado graso asociada a disfunción metabólica (FIB-4 < 1,30) y con indicación de reducción de peso (n = 15). El grupo control siguió una dieta mediterránea (DM) semipersonalizada para la reducción de peso, de acuerdo con las recomendaciones de la Sociedad Española para el Estudio de la Obesidad (SEEDO). El grupo intervención, además de la DM, tomó tres cápsulas diarias de MetioNac®. Resultados: en comparación con el grupo de control, los sujetos que tomaron MetioNac® mostraron reducciones significativas (p < 0.05) en los niveles de TG y VLDL-c, así como en los niveles de colesterol total, LDL-c y glucosa. También mostraron niveles elevados de HDL-c. Los niveles de AST y ALT disminuyeron después de la intervención con MetioNac®, pero esta disminución no fue estadísticamente significativa. También se observó una pérdida de peso en ambos grupos. Conclusión: la suplementación con MetioNac® puede proteger contra la hiperlipidemia, la insulinorresistencia y el sobrepeso en pacientes con síndrome metabólico. Sin embargo, es necesario realizar más estudios y seleccionar un mayor número de participantes.

Prevalence of Genetic Diamine Oxidase (DAO) Deficiency in Female Patients with Fibromyalgia in Spain.

Diamine oxidase (DAO) is an enzyme that metabolizes intestinal histamine. Single nucleotide polymorphisms (SNPs) of the Amine Oxidase Copper Containing 1 (AOC1) gene can lead to low enzymatic activity or functionality in histamine metabolism. This study aimed to determine the prevalence of DAO deficiency for four variants of the AOC1 gene, p.Thr16Met (rs10156191), p.Ser332Phe (rs1049742), p.His664Asp (rs1049793), and c.691G > T (rs2052129), in 98 Spanish women with fibromyalgia between the ages of 33 and 60 years, and compare the distribution of allelic and genotypic frequencies with those of European population samples in Hardy-Weinberg equilibrium extracted from the Allele Frequency Aggregator (ALFA) database. The patients' DNA was extracted, and analyzed using SNPE Multiplex (Single Nucleotide Primer Extension). The prevalence of genetic DAO deficiency was 74.5% based on the four variants of the AOC1 gene. SNP deficits were found at frequencies of 53.1% for p.Thr16Met, 49% for c.691G > T, 48% for p.His664Asp, and 19.4% for p.Ser332Phe. The allele and genotypic frequencies of the women with fibromyalgia did not differ from the European population. Variants of the AOC1 gene that are associated with genetic DAO deficiency could serve as a disruptive biomarker in patients with fibromyalgia. This study was registered in ClinicalTrials.gov Identifier: NCT05389761.

Cumulative effect of AOC1 gene variants on symptoms and pathological conditions in adult women with fibromyalgia: a pilot study.

Introduction: The amine oxidase copper-containing 1 (AOC1) gene encodes for the diamine oxidase (DAO) enzyme. DAO is an enzyme that catabolizes some molecules, including histamine, and is the degradative enzyme in the polyamine catabolic pathway that is active in intestinal mucosal cells. Variants of AOC1 are associated with reduced DAO activity, resulting in accumulation of high levels of histamine and causing a wide range of neurological, gastrointestinal, and epidermal disorders, which are present in people with fibromyalgia. This study aimed to evaluate the impact of four AOC1 gene variants, namely, rs10156191, rs1049742, rs1049793, and rs2052129, on fibromyalgia symptoms measured by the Fibromyalgia Impact Questionnaire (FIQ), such as sleep disorders, atopic dermatitis, migraine, gastrointestinal (GI) disorders, allergies, and intolerances, in adult women with fibromyalgia. Methods: The sample consisted of 100 unrelated women with fibromyalgia between 33 and 60 years of age (48.48 years ±7.35), whose were diagnosed by a rheumatologist based on symptoms such as pain, stiffness, and fatigue. Single-nucleotide polymorphisms (SNPs) of AOC1 were identified using oral mucosa samples collected following a standard hygiene protocol. DNA was extracted, and gene variants of interest were analyzed using multiplex single-nucleotide primer extension (SNPE). Clinical data were collected using the FIQ and a series of variables that quantified the intensity and frequency of the symptoms. Results: The minor allele frequencies of rs10156191, rs1049742, rs1049793, and rs2052129 were 31.5, 10, 32.5, and 27%, respectively. Each variant was found to be in Hardy-Weinberg equilibrium, but partial linkage disequilibrium between AOC1 SNPs is suspected. The results show that fibromyalgia symptoms measured using the FIQ tend to increase with the number of risk alleles and that the intensity of dry skin and low stool consistency may be associated with an increase in the number of these alleles. Conclusion: This study constitutes the first step in investigating associations between fibromyalgia symptoms and candidate variants of the AOC1 gene in DAO enzyme activity. Identification of reduced DAO activity may improve the quality of life and treatment of symptoms in fibromyalgia patients.

[Malnutrition prevalence at admission to Hospital General Nuestra Señora del Prado, Talavera de la Reina]. / Prevalencia de la desnutrición al ingreso en los pacientes del Hospital General Nuestra Señora del Prado, Talavera de la Reina.

INTRODUCTION: Introduction: malnutrition is a global problem. In developed countries, malnutrition due to alterations in the population's eating habits or the presence of disease cannot be ignored, and affects hospitalized patients in particular. Objective: to determine the prevalence of malnutrition risk upon admission to Hospital General Nuestra Señora del Prado in Talavera de la Reina (Toledo, Spain). Methods: this was an observational, cross-sectional, descriptive study. From September 2017 to October 2018 all patients admitted to hospital who met the selection criteria were assessed for nutritional status using the NRS-2002® test. Anthropometric and clinical data were collected from patients at nutritional risk (NRS-2002® score ≥ 3). The malnutrition observed was diagnosed according to type and severity, and nutritional indications were given, which were recorded in the report to the clinician and in the discharge report. Results: a total of 476 patients took the NRS-2002® test, which detected risk of malnutrition upon admission in 137 (28.8 %; 95 % CI: 24.8 % to 33.0 %). Average BMI (SD) was 24.6 (5.4) kg/m2. The dietitian-nutritionist recommended nutritional supplementation for 78.4 % of patients, and coding of nutritional status (ICD-10) for 82.1 %. In the discharge report, more than 70 % of these recommendations were omitted. Conclusions: in all, 28.8 % of the patients analyzed were at risk of malnutrition or undernourished on admission. Hospital malnutrition continues to be a problem, so it is vitally important that screening methods be included at admission to allow early nutritional intervention in hospitalized patients, and that trained healthcare personnel be incorporated to this end.

INTRODUCCIÓN: Introducción: la malnutrición es un problema global. En los países desarrollados no puede ignorarse la desnutrición debida a las alteraciones en los hábitos alimentarios de la población o a la presencia de enfermedades, lo que afecta de forma destacable a los pacientes hospitalizados. Objetivo: determinar la prevalencia del riesgo de desnutrición al ingreso en el Hospital General Nuestra Señora del Prado de Talavera de la Reina (Toledo, España). Métodos: estudio observacional, transversal y descriptivo. Desde septiembre de 2017 a octubre de 2018, a todos los pacientes que ingresaban en el hospital y cumplían los criterios de selección se les realizó un cribado nutricional mediante el test NRS-2002®. Se recogieron datos antropométricos y clínicos de los pacientes en riesgo nutricional (puntuación NRS-2002® ≥ 3). Se diagnosticó la desnutrición observada según su tipología y gravedad, emitiendo indicaciones nutricionales recogidas en el informe al clínico y en el informe al alta. Resultados: en total, 476 pacientes realizaron el test NRS-2002®, detectándose riesgo de desnutrición al ingreso en 137 (28,8 %; IC 95 %: 24,8 % a 33,0 %). El IMC promedio (DE) de estos fue de 24,6 (5,4) kg/m2. La dietista-nutricionista recomendó al 78,4 % de los pacientes una suplementación nutricional, y en el 82,1 % de los casos la codificación del estado nutricional (CIE-10). En el informe de alta se omitieron más del 70 % de estas recomendaciones. Conclusiones: el 28,8 % de los pacientes analizados estaban en riesgo de desnutrición o desnutridos al ingreso. La desnutrición hospitalaria continúa siendo un problema en la actualidad, por lo que resulta de vital importancia incluir métodos de cribado al ingreso que permitan una intervención nutricional precoz en el paciente hospitalizado, así como la incorporación de personal sanitario formado para su realización.

Safety of bloodless autologous stem cell transplantation in Jehovah's Witness patients.

Due to the curative potential and improvement in progression-free survival (PFS), high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is considered the standard of care for several hematologic malignancies, such as multiple myeloma, and lymphomas. ASCT typically involves support with blood product transfusion. Thus, difficulties arise when Jehovah's Witness patients refuse blood transfusions. In order to demonstrate the safety of performing "bloodless" ASCT (BL-ASCT), we performed a retrospective analysis of 66 Jehovah's Witnesses patients who underwent BL-ASCT and 1114 non-Jehovah's Witness patients who underwent transfusion-supported ASCT (TF-ASCT) at Cedars-Sinai Medical Center between January 2000 and September 2018. Survival was compared between the two groups. Transplant-related complications, mortality, engraftment time, length of hospital stay, and number of ICU transfers were characterized for the BL-ASCT group. One year survival was found to be 87.9% for both groups (P = 0.92). In the BL-ASCT group, there was one death prior to the 30 days post transplant due to CNS hemorrhage, and one death prior to 100 days due to sepsis. Based on our data, BL-ASCT can be safely performed with appropriate supportive measures, and we encourage community oncologists to promptly refer JW patients for transplant evaluation when ASCT is indicated.

Effects of Drugs and Excipients on Hydration Status.

Despite being the most essential nutrient, water is commonly forgotten in the fields of pharmacy and nutrition. Hydration status is determined by water balance (the difference between water input and output). Hypohydration or negative water balance is affected by numerous factors, either internal (i.e., a lack of thirst sensation) or external (e.g., polypharmacy or chronic consumption of certain drugs). However, to date, research on the interaction between hydration status and drugs/excipients has been scarce. Drugs may trigger the appearance of hypohydration by means of the increase of water elimination through either diarrhea, urine or sweat; a decrease in thirst sensation or appetite; or the alteration of central thermoregulation. On the other hand, pharmaceutical excipients induce alterations in hydration status by decreasing the gastrointestinal transit time or increasing the gastrointestinal tract rate or intestinal permeability. In the present review, we evaluate studies that focus on the effects of drugs/excipients on hydration status. These studies support the aim of monitoring the hydration status in patients, mainly in those population segments with a higher risk, to avoid complications and associated pathologies, which are key axes in both pharmaceutical care and the field of nutrition.

Body Composition, Dietary, and Gustatory Function Assessment in People With Alzheimer's Disease.

OBJECTIVES: Observe the association of foods habits, body composition, lifestyle habits, and loss of gustatory function with Alzheimer's disease (AD). METHODS: This comparative study enrolled 75 patients with AD (mean age 77.5 years) and 267 healthy volunteers (mean age 73 years). Weight, height, body mass index (BMI), body fat, visceral fat, muscle mass, and waist circumference were measured. Adherence to the Mediterranean diet was measured by the Mediterranean-Diet-Adherence Screener. Gustatory function was investigated using a threshold and triangle test. RESULTS: Cases with AD presented lower BMI and weight and higher sleep hours, being statistically significant the difference between cases and controls ( P = .02; P = .001; P = .001, respectively). Patients with AD showed lower adherence to exercise and Mediterranean diet as shown by the Mediterranean Diet Adherence Screener-score (8.12 ± 2.5 vs 8.65 ± 2.4). The gustatory function was impaired in patients with AD when compared to controls. CONCLUSION: Patients with AD show worst outcomes in terms of anthropometric measurements, lifestyle habits (diet, exercise), and gustatory function than controls.

Detección de la alteración del metabolismo glucídico y resistencia a la insulina en una muestra piloto infantil: Aproximación metabolómica / Detection of impaired glucidic metabolism and insulin resistance in a pilot child sample

Resumen Introducción: La metabolómica permite estudiar la resistencia a insulina (RI), un factor de riesgo de pre-diabetes y diabetes. Quantose IR TM es el único test que mide la RI mediante la abrazadera hiperinsulinémica euglicémica. Objetivo: Se comprobó la eficacia de un test metabolómico en la detección de marcadores de RI en población infantil. Materiales ymétodos: Once niños, de edad 8,54±3,53 años y con factores de riesgo de diabetes, fueron reclutados del Hospital El Escorial. Se estableció como criterio diagnóstico para la prediabetes el estándar de la Asociación Americana de Diabetes (ADA) (HbA1C 5,7-6,4% y glucosa basal 100-125mg/dl). Se compararon las analíticas de sangre con la prueba de Quantose IR TM , estudiando el perfil del metaboloma relacionado con la RI (ácido alfa-hidroxibutírico, ácido oleico, linoleo-glicerofosfocolina e insulina). Su análisis generó una puntuación Quantose © (escala 0-100), siendo >63 RI. Resultados: Ningún sujeto cumplió el criterio de la ADA para prediabetes: HbA1C fue 5,3±0,18 % y glucosa 86,6±5,6 mg/dl. Por el contrario, 10 sujetos cumplieron criterios del test Quantose IR TM para la RI (score: 78,09 ± 9,24 (>63)). Conclusiones: El test Quantose IR TM mide el porcentaje de hemoglobina unida a glucosa dentro de los glóbulos rojos. Permite prever el riesgo de diabetes, y tomar medidas preventivas.

Abstract Introduction: Metabolomics enables the study of insulin resistance (IR), a risk factor for pre-diabetes and diabetes. Quantose IRTM is the only test that measures IR using the euglycemic hyperinsulinemic clamp. Objective: The effectiveness of a metabolomic test for the detection of RI markers in a child population was verified. Materials and methods: Eleven children aged 8.54 ± 3.53 years with diabetes risk factors were recruited from the El Escorial Hospital. The American Diabetes Association (ADA) Standards (5,7-6,4% HbA1C and 100-125 mg/dl basal glucose) were established as diagnostic criteria for prediabetes. Blood tests were compared to the Quantose IRTM assay studying the metabolomic profile related to IR (alpha-hydroxybutyric acid, oleic acid, linoleo-glycerophosphocoline and insulin). This analysis generated a Quantose © score of IR > 63. Results: None of the subjects met the ADA criteria for prediabetes: HbA1C=5,3±0,18 and glucose=86,6± 5,6 mg/dl. On the contrary, 10 subjects met the Quantose IRTM test criterion for IR (score: 78,09 ± 9,24 (>63)). Conclusions: The Quantose IRTM test measures the percentage of glucose bound hemoglobin within red blood cells. This assay makes it possible to predict diabetes risk and take preventive measures.